Multiple subconjunctival bevacizumab for advanced primary pterygium.

Effectiveness of multiple subconjunctival bevacizumab injections in advanced primary pterygium was studied the first time. Treatment produced regression of pteryium and improvement of best-corrected visual acuity from 20/100 to 20/60 at 6-mont follow-up. Off-label short-term use of sbconjunctival bevaciumab is effective.

Association of contrast sensitivity with LogMAR visual acuity and glycosylated hemoglobin in non-insulin dependent diabetes mellitus.

A tertiary care center-based prospective case-control study was undertaken to evaluate the association of contrast sensitivity with LogMAR visual acuity and glycosylated hemoglobin (HbA1c) in 205 cases of non-insulin dependent diabetes mellitus and 115 controls. LogMAR visual acuity and contrast sensitivity were scored using ETDRS and Pelli-Robson charts, respectively. Bivariate correlation between contrast sensitivity and LogMAR visual acuity showed significant inverse correlation in cases without retinopathy (r = -0.

Topical bevacizumab for corneal neovascularization after penetrating keratoplasty.

Purpose: To evaluate the efficacy of topical bevacizumab for corneal neovascularization in graft rejection.

Methods: A 55-year-old man presented with corneal neovascularization and graft rejection 6 months following penetrating keratoplasty (triple procedure) in the left eye. His best-corrected visual acuity (BCVA) was counting fingers at 1 meter.

Mesenchymal chondrosarcoma of the orbit: a report of two cases and review of the literature.

Mesenchymal chondrosarcoma, an uncommon lesion in bone and extraskeletal tissue, is extremely rare in the orbit. Two cases of orbital mesenchymal chondrosarcoma in young adults presenting with proptosis and diminution of vision are reported. The diagnosis was established by histopathological examination in both cases, which showed undifferentiated mesenchymal cells with islands of cartilage.